跳至主要内容
临床试验/CTRI/2021/07/034834
CTRI/2021/07/034834招募中未知

A real-world observational study on Diabetes Mellitus patients administering dual combination therapy of Teneligliptin and MetformIn to evaluate REnal function. - ADMIRE STUDY

Mankind Pharma Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Male or female patients, age ââ?°Â¥ 18 to ââ?°Â¤ 85 years.
  • 2. Uncontrolled Type 2 diabetes with a haemoglobin A1c (HbA1c) ââ?°Â¥7.0 percent.
  • 3. eGFR (MDRD) at screening > 60 mL/min/1.73m2
  • 4. Patients who are prescribed Teneligliptin and Metformin combination therapy as part of routine clinical practice.

排除标准

  • 1. Female patients who are pregnant or breast feeding
  • 2. Patients with known liver or kidney dysfunction
  • 3. Patients who are suspected of or known to have an intolerance to Teneligliptin or Metformin.
  • 4. Presence of any other clinically significant disease or laboratory findings that in the Investigators opinion may affect the study outcomes or continued participation of patient in the study.
  • 5. Participation in another study concurrently or within 4 weeks prior to the Screening Visit

研究者

发起方
Mankind Pharma Ltd

相似试验